Drug Approval | August 22, 2023
Jiangsu Hengrui Pharmaceuticals gets NMPA approval of oteseconazole Ccapsules
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Oteseconazole Capsules were found to be safe and more effective than fluconazole
The Long-term Safety Trial was approved to be conducted by China National Medical Products Administration (NMPA) on 18 April 2023
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Tafasitamab is conditionally approved by both the U.S. Food and Drug Administration and European Medicines Agency
This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
One in two women with advanced ovarian cancer has an HRD-positive tumor
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
Ascletis is China's first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA
Subscribe To Our Newsletter & Stay Updated
